Optical and Multimodality Molecular Imaging Insights Into Atherosclerosis

doi:10.1161/ATVBAHA.108.165530

Journal List > NIHPA Author Manuscripts

Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2009 September 1.

Published in final edited form as:

Arterioscler Thromb Vasc Biol. 2009 July; 29(7): 1017–1024.

Published online 2009 April 9. doi: 10.1161/ATVBAHA.108.165530.

PMCID: PMC2733228

NIHMSID: NIHMS130290

Optical and Multimodality Molecular Imaging Insights Into Atherosclerosis

Farouc A. Jaffer, Peter Libby, and Ralph Weissleder

Donald W. Reynolds Cardiovascular Clinical Research Center (F.A.J., P.L., R.W.) Harvard Medical School; the Cardiovascular Research Center and Cardiology Division (F.A.J.), the Center for Molecular Imaging Research (F.A.J., R.W.), and the Center for Systems Biology (R.W.), Massachusetts General Hospital; and the Cardiovascular Division (P.L.), Brigham and Women's Hospital, Boston, Mass

Correspondence to Farouc Jaffer, MGH CVRC, Simches Research Building, Room 3206, 185 Cambridge Street, Boston, MA 02114. E-mail fjaffer/at/mgh.harvard.edu

The publisher's final edited version of this article is available at Arterioscler Thromb Vasc Biol.

Abstract

Imaging approaches that visualize molecular targets rather than anatomic structures aim to illuminate vital molecular and cellular aspects of atherosclerosis biology in vivo. Several such molecular imaging strategies are poised for rapid clinical application. This review describes the growing role of in vivo optical molecular imaging in atherosclerosis and highlights its ability to visualize atheroma inflammation, calcification, and angiogenesis. In addition we discuss advances in multimodality probes, both in the context of multimodal imaging as well as multifunctional, or “theranostic,” nanoparticles. This review highlights particular molecular imaging strategies that possess strong potential for clinical translation.

Keywords: atherosclerosis, molecular imaging, optical, fluorescence, multimodality, nanoparticle

Imaging methods to identify high-risk atherosclerotic plaques have traditionally focused on stenosis detection, yet the majority of plaques responsible for acute coronary syndromes originate from non–flow-limiting lesions.¹ Furthermore, numerous experimental and clinical studies reveal that biological processes such as inflammation modulate the risk of plaque disruption and consequent myocardial infarction and stroke.² High-resolution molecular imaging approaches aim to bridge the gap between in vivo imaging and biological characterization of atheromata. Using novel targeted and activatable imaging agents, molecular imaging strategies now offer in vivo readouts for a diverse array of biological processes.³^,⁴ This review discusses advances in atherosclerosis detection enabled by optical, specifically near-infrared fluorescence, molecular imaging, as well as by multimodality reporter agents.

Near-Infrared Fluorescence Molecular Imaging

The interaction of light with matter has yielded a number of powerful imaging modalities including fluorescence, absorption and Raman spectroscopy, optical coherence tomography, bioluminescence, and angioscopy (supplemental Table I, available online at http://atvb.ahajournals.org). Fluorescence imaging, in particular, near-infrared fluorescence (NIRF) imaging (excitation 650 to 900 nm), provides a highly versatile platform for in vivo molecular imaging.⁵^,⁶ Advantages of fluorescence as a molecular imaging modality include: (1) picomolar molecular sensitivity; (2) versatile targeting platforms such as peptides, proteins, antibody fragments, nanoparticles, phage, and aptamers; (3) a number of fluorescence detection imaging systems with microscopic resolution (epifluorescence, laser scanning, confocal, and multiphoton microscopy), mesoscopic resolution (optoacoustic imaging, fluorescence tomography, optical projection tomography), and macroscopic resolution (reflectance imaging, fluorescence-mediated tomography); and (4) a strong track record of clinical translation, with fluorescence imaging systems available for retinal angiography (via fluorescein or indocyanine green enhancement), endoscopy, bronchoscopy, coronary angioscopy, and coronary arterial bypass graft imaging.⁷

Compared to fluorescence imaging in the visible light or mid IR range, fluorescence imaging in the NIR bandwidth offers (1) markedly less photon absorption from blood hemoglobin, lipid, and water, enabling photon transmission centimeters deep into the body; and (2) substantially reduced tissue autofluorescence, enabling higher sensitivity detection of targeted NIRF molecular imaging agents against a low background (supplemental Figure I). For a greater discussion of the physics underlying efficient NIR photon delivery through tissues, fluorescence chemistry synthesis approaches, and fluorescence hardware systems, the interested reader can consult several reviews.⁵^–⁷

In Vivo NIRF Molecular Imaging of Atherosclerosis

Imaging of Protease Activity

Inflammatory and destructive matrix metalloproteinases (eg, MMP-1, -2, -3, -7, -8, -9, -12, -13, and disintegrin metalloproteinases) cysteine proteases (eg, cathepsins S, K, B, and L), and serine proteases (eg, tissue plasminogen activator and urokinase-type plasminogen activator) are implicated in atherogenesis, plaque expansion, and plaque rupture.⁸ Augmented protease activity is an indicator of a high-risk plaque subtype⁹ and therefore represents an important molecular imaging target for atherosclerosis.

Protease-Activatable NIRF Imaging Agents

The chemical design and imaging amplification strategy of protease-activatable reporters¹⁰ are discussed in detail in the online supplemental materials.

Noninvasive Fluorescence-Mediated Tomography of Plaque Protease Activity

Fluorescence-mediated tomography (FMT) uses temporally and spatially resolved illuminators and detectors to detect NIR fluorochromes noninvasively and deep within the body.⁵^,⁶ Advanced mathematical algorithms resolve photons deep within scattering tissue and render a quantitative 3-dimensional image of NIR fluorescence.¹¹ Feasibility of noninvasive FMT of cysteine protease activity in atheromata first used apolipoprotein E–deficient (apoE^−/− mice).¹² Twenty-four hours after injection of a first generation protease-activatable NIRF imaging agent (Prosense680, dose 5 nmol per mouse, 0.25 μmol/kg), noninvasive FMT demonstrated focal NIRF signal in the atherosclerotic aorta (Figure 1

). Ex vivo macroscopic fluorescence reflectance imaging (FRI) demonstrated colocalization of NIRF signal with Sudan IV–stained plaques, and microscopic analyses demonstrated that the plaque NIRF signal colocalized with the lysosomal cysteine protease cathepsin B. This study demonstrated that FMT noninvasively visualized augmented plaque protease activity and established cathepsin B as inflammatory imaging biomarker for atherosclerosis. The first-generation of protease activatable agent is currently under development for clinical studies of atheroma and tumor cysteine protease activity.

Figure 1

A, Schematic mechanism of activation for a lysine-cleavable protease activatable agent (Prosense). The injectable imaging agent is a long-circulating high-molecular-weight compound (≈550 kDa) consisting of a poly-l-lysine backbone and protective (more ...)

To visualize noninvasively plaque gelatinolytic activity in vivo, Deguchi et al used a second-generation protease-activatable agent to investigate MMP-2 and MMP-9 activity.¹³ The MMP-2 and MMP-9 activity agent was synthesized by incorporating the gelatinase sensitive peptide substrate GGPRQITAG into the first-generation protease activatable agent.¹⁴ Cholesterol-fed apoE^−/− deficient mice received the gelatinase NIRF imaging agent (dose 8 nmol per mouse; 0.4 μmol/kg). After 24 hours, FMT revealed augmented NIRF signals in areas corresponding to the aortic root, arch and thoracic aorta, known sites of atherosclerosis in apoE^−/− mice. Ex vivo FRI and NIRF microscopy validated the in vivo imaging findings. In addition, in situ zymography using quenched fluorescein-labeled gelatin demonstrated colocalization of plaque gelatinase NIRF signal with fluorescence signal from fluorescein.

As NIR photons may potentially travel >5 centimeters deep into the body,⁵^,⁶ noninvasive FMT systems may eventually detect NIRF signals from human carotid atheromata or from abdominal aortic aneurysms or plaques. Additional gains in FMT imaging may result from the use of nonfluid contact based imaging systems, integrated FMT-computed tomography (CT) systems, and multimodality imaging agents (discussed below).

Intravital Fluorescence Microscopy (IVFM) of Plaque Cathepsin K Activity

A novel NIRF approach to image cathepsin K protease activity in atherosclerosis¹⁵ is discussed in the online supplemental materials.

Intravascular NIRF Catheter Sensing of Cysteine Protease Activity in Atherosclerosis

To develop a highly clinically translatable approach to image proteolytically active atherosclerosis in coronary-sized vessels, we developed an intravascular NIRF sensing approach based on a clinically used optical coherence tomography (OCT) guide wire.¹⁶ The guide wire was percutaneously tested in cholesterol-fed balloon-injured rabbits harboring inflammatory proteases in iliac atheromata. Twenty-four hours before imaging, the rabbits received an injection of the first-generation protease-activatable agent for cysteine proteases (Prosense750, dose 600 nmol/kg). In vivo, the NIRF guide wire detected strong signal emanating from inflamed plaques (Figure 2

). Multiple catheter pullbacks in vivo yielded high plaque target-to-background ratios (TBR 6.8 versus saline control 1.3) through blood, without the need for flushing or occlusion, affirming the favorable photonic transmission properties of the NIR window. A good correlation was noted between in vivo and ex vivo TBR measurements (r=0.82), and correlative fluorescence microscopy confirmed that the microscopic NIRF signal colocalized with immunoreactive cathepsin B. As the NIRF guide wire is a clinical platform and the Prosense agent should enter clinical trials in 2010 (personal communication), the current catheter based approach could enable identification of high-risk inflamed coronary atheromata.

Figure 2

Real-time intravascular NIRF imaging of protease activity. A, The intravascular catheter was modified from a clinical optical coherence tomography guide wire used in human coronary artery imaging. NIR light (red) was emitted in a 90-degree arc and focused (more ...)

Imaging of Plaque Osteogenesis

The spatiotemporal distribution of plaque osteogenic and inflammatory activity was concomitantly visualized in atheromata using IVFM technology¹⁷ and is discussed in detail in the online supplemental materials and supplemental Figure II.

Imaging of Plaque Angiogenesis

NIRF imaging of neoangiogenic vasculature in atheroma¹⁸^,¹⁹ is discussed in the online supplemental materials.

Emerging NIRF Imaging Agents

Promising NIRF agents for in vivo optical molecular imaging of atherosclerosis (Table) include sensors for detection of apoptosis by annexin sensors,²⁰ oxidative stress by hypochlorous acid,²¹ integrin sensors based on RGD,²² or small molecules (Intregrisense680), new plaque targeted nanoparticulate NIRF agents,²³ cysteine protease activity based probes,²⁴ NIR fluorescent deoxyglucose sensors for glycolytic flux/metabolism,²⁵^,²⁶ similar to fluorine-18 deoxyglucose (¹⁸FDG) for PET metabolism studies, and matrix metalloproteinase presence via modified C-5– disubstituted baribiturates.²⁷

Table

Promising Near-Infrared Fluorescence (NIRF) and Multimodal Molecular Imaging Agents for Atherosclerosis Detection

Multimodal Probes: Imaging of Atherosclerosis

Multimodal or multi-functional probes for molecular imaging fall into 2 categories: (1) probes that enable multiple in vivo imaging molecular readouts (multimodality imaging probes, ie, detectable by optical, MRI, and nuclear approaches simultaneously), and (2) probes that enable in vivo imaging and concomitant targeted therapy (therapeutic and diagnostic, or “theranostic,” probes). Favorable multimodality imaging probes harness capabilities from complementary imaging modalities to (1) achieve high sensitivity and high spatial resolution (eg, probes with reporter capabilities for both positron emission tomography and MRI) and to (2) enable both noninvasive and invasive molecular imaging (eg, via probes with MRI and NIR fluorescence reporter capabilities²⁸). A common platform for multimodality probes uses MRI to obtain concomitant anatomic, chemical, and physiological information.

Multimodality Imaging of Plaque Macrophages

A powerful platform for multimodality molecular imaging of lesional macrophages uses dextran-coated crystalline iron oxide magnetic nanoparticles (MNPs). Iron-oxide MNPs are superparamagnetic imaging agents that exert field-dependent R2 and R1 effects. After phagocytosis by tissue macrophages, MNPs induce strong relaxation effects detectable on T2-weighted MRI, and more recently by off-resonance positive contrast approaches.²⁹^–³² A class of MNPs show promise clinically in prostate cancer³³ and carotid atherosclerosis MRI studies.³⁴^–³⁸

The development of a multimodality MNPs derivatized with an NIR fluorochrome²⁸^,³⁹ enabled dual-modality imaging of plaque macrophages by MRI and intravital microscopy.¹⁷^,⁴⁰^,⁴¹ In a very recent advance, Nahrendorf et al developed a trimodality iron oxide–based MNPs (TNP) for concomitant PET, MRI, and NIRF imaging of plaque macrophages (Figure 3

).⁴² The trimodality nanoparticle consists of 4 components: (1) an iron oxide core for T2-weighted in vivo MRI contrast; (2) a cross-linked dextran outer shell enabling internalization by macrophages; (3) the positron emitter copper-64, attached to the dextran coat via diethylene triamine pentaacetic acid (DTPA) for in vivo PET detection; and (4) the NIR fluorochrome VT680 (ex 680 nm/em 700 nm) for fluorescence detection by in vivo NIRF imaging, fluorescence microscopy, and flow cytometry.

Figure 3

In vivo imaging of macrophages using a trimodality nanoparticle (TNP) for PET, MRI, and NIRF imaging. The copper-64 radiolabeled and NIR fluorochrome-labeled iron oxide TNP was injected into apoE^−/− mice or control mice without atherosclerosis. (more ...)

In vivo testing of TNP was performed in apoE^−/− mice using in vivo PET/CT and in vivo 7.0 T MRI systems. Several important results were obtained. First, TNP permitted concomitant in vivo MRI and PET imaging of plaque macrophages (Figure 3

), with a 7- to 20-fold in vivo increase in sensitivity by PET- versus MRI-based detection. Second, the relatively longer half-life of copper-64 (12.7 hours versus fluorine-18, 1.8 hours) enabled autoradiographic studies that demonstrated TNP deposition into aortic atheromata (0.3% injected dose/gram tissue). Third, the NIRF component permitted precise cellular localization and quantification fluorescence studies following radio-isotope decay, and demonstrated that TNP deposited primarily in plaque macrophages (Figure 3

). Fourth, compared to 18-fluorodexoyglucose (¹⁸FDG), a clinical PET tracer for imaging plaque metabolism/inflammation,³^,⁴ TNP provided favorable plaque signal enhancement (standardized uptake value [SUV] 1.2 versus 0.8, P<0.05).

As starched-based iron oxide MNPs have been tested clinically,³³^–³⁸ the TNP agent may ultimately enable clinical noninvasive PET/CT and MRI detection of carotid plaque macrophages, particularly as promising integrated PET/MRI scanners⁴³ translate into the clinic to provide 1-stop molecular, anatomic, and physiological imaging capabilities. In addition, the fluorescence capability of TNP could enable invasive catheter-based NIRF detection¹⁶ of coronary plaque macrophages.

Vascular Cell Adhesion Molecule–1

The development of multimodal NIRF and MRI nanoparticles for in vivo imaging of VCAM-1 expression⁴⁴^,⁴⁵ is discussed in detail in the online supplemental materials.

Emerging Multimodality Imaging Probes

Available multimodality probes with potential utility in atherosclerosis (Table) include apoptosis sensors for NIRF/MRI⁴⁶ and angiogenic-targeted perfluorocarbon paramagnetic emulsions for MRI/ultrasound.⁴⁷ Additional promising nanoparticle platforms that could be useful for in vivo multimodality imaging include perfluorocarbon based microemulsions, microbubbles, micelles, quantum dots, liposomes, and lipoproteins, and are comprehensively discussed in several recent reviews.⁴⁸^,⁴⁹

Multimodal Theransotic Probes: Targeted Imaging and Therapy of Atherosclerosis

Integrated diagnostic imaging and therapeutic molecules, or “theranostic” particles, are increasingly appreciated as a valuable advance for targeted therapy. Addition of a diagnostic imaging moiety to a targeted therapeutic enables temporal and spatial monitoring of the therapeutic agent. Imaging information in theranostics can be used to confirm delivery of therapy at the desired target, identify the need for modified dosing/redosing strategies, quantify and track the “molecular efficacy” of the therapeutic in vivo, and identify likely responders and nonresponders at the onset of therapy. Although theranostics are in the early stages for targeting atherosclerosis, several recent advances merit discussion.

Integrated Imaging and Therapy of Plaque Angiogenesis

Reduction of neovasculature in atheromata is an intriguing strategy to limit plaque growth and intraplaque hemorrhage.⁵⁰^,⁵¹ Building on an integrin α_vβ₃-targeted perfluorocarbon platform for molecular MRI of plaque angiogenesis,⁴⁷ Winter et al developed an antiangiogenic atherosclerosis theranostic strategy by incorporating fumagillin, a naturally secreted antibiotic from Aspergillus fumigatus, into the surfactant layer of an integrin α_vβ₃ targeted nanoparticle.⁵² Hyperlipidemic rabbits with aortic atheromata were then injected with a single dose of control MNPs or fumagillin-targeted MNPs (≈26 μg/kg body weight). Immediate postinjection MRI of aortic plaques demonstrated similar evidence of angiogenesis for both groups. After 1 week, rabbits in both groups were reinjected with the control MNPs (angiogenic targeted MNPs without fumagillin). Rabbits that originally received the fumagillin MNPs showed a marked reduction of plaque angiogenesis in vivo (>60% reduction in averaged aortic MRI signal enhancement), whereas control rabbits showed unchanged levels of plaque angiogenesis. Furthermore, the initial signal enhancement on the original MRI scan predicted the net fumagilin MNP-mediated reduction in plaque angiogenesis (R²=0.62). In vivo MRI findings were corroborated by PECAM immunohistochemical analyses demonstrating a >60% reduction in the number of neovessels per plaque section in the fumagillin MNP group compared to the control MNP group. In a very recent study, Winter et al further used fumagillin MNPs to demonstrate an antiangiogenic synergism of fumagillin and statin therapy by in vivo MRI.⁵³ Even more recently, a dual angiogenesis-targeted fumagillin theranostic nanoparticle (integrin α_vβ₃ and integrin α₅β₁) appears more effective than a single angiogenesis-targeted fumagillin NP (integrin α_vβ₃).⁵⁴

Emerging Theranostic Agents for Atherosclerosis

Additional agents (Table) such as photosensitizers with intrinsic NIR fluorescence capabilities⁵⁵ or those with discrete NIR fluorochromes⁵⁶ could offer the ability to characterize inflamed atheromata before photodynamic therapy. Another platform with substantial promise for atherosclerosis includes NIR fluorescent magnetic nanoparticles carrying therapeutic siRNA molecules.⁵⁷

Conclusions

Molecular imaging of atherosclerosis offers new opportunities to study the evolution of biology in vivo, as well as new clinically translatable strategies to identify high-risk coronary and carotid plaques. Rapid growth of optical, specifically near-infrared fluorescence, molecular imaging strategies show promise for imaging plaque inflammation, osteogenic activity, and angiogenesis with increasingly clinical-type imaging systems such as intravascular catheters or noninvasive tomography. Additional growth in multimodality probe technology, with imaging agents detectable by 2 or more imaging systems, as well as theranostic agents enabling spatiotemporal monitoring of targeted therapies, are also poised to strengthen emerging in vivo biological approaches to understanding and treating atherosclerotic vascular disease.

Supplementary Material

suppl

Click here to view.^{(457K, pdf)}

Acknowledgments

Sources of Funding: This work was supported by the Donald W. Reynolds foundation (F.J., P.L., R.W.), Howard Hughes Medical Institute Early Career Award (F.J.), and American Heart Association Scientist Development Grant (F.J.). We gratefully acknowledge support from NIH grants UO1-HL080731, RO1-HL078641, and R24-CA92782.

Footnotes

Disclosures: Dr Jaffer is a consultant to VisEn Medical. Dr Weissleder is a shareholder in VisEn Medical.

References

1. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol. 1986;7:472–478. [PubMed]

2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–519. [PubMed]

3. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation. 2007;116:1052–1061. [PubMed]

4. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953–957. [PubMed]

5. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med. 2003;9:123–128. [PubMed]

6. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol. 2005;23:313–320. [PubMed]

7. Chang K, Jaffer F. Advances in fluorescence imaging of the cardiovascular system. J Nucl Cardiol. 2008;15:417–428. [PubMed]

8. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res. 2006;69:625–635. [PubMed]

9. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–1672. [PubMed]

10. Weissleder R, Tung CH, Mahmood U, Bogdanov A., Jr In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999;17:375–378. [PubMed]

11. Ntziachristos V, Tung CH, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med. 2002;8:757–760. [PubMed]

12. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002;105:2766–2771. [PubMed]

13. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006;114:55–62. [PubMed]

14. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001;7:743–748. [PubMed]

15. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, Kohler RH, Shi GP, Libby P, Weissleder R. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation. 2007;115:2292–2298. [PubMed]

16. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, Ntziachristos V, Libby P, Weissleder R. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation. 2008;118:1802–1809. [PubMed]

17. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116:2841–2850. [PubMed]

18. Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, Halin C, Castellani P, Zardi L, Hofer CK, Montani M, Neri D, Luscher TF. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res. 2004;95:1225–1233. [PubMed]

19. Graf K, Dietrich T, Tachezy M, Scholle FD, Licha K, Stawowy P, Grafe M, Hauff P, Fleck E. Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis. Mol Imaging. 2008;7:68–76. [PubMed]

20. Ntziachristos V, Schellenberger EA, Ripoll J, Yessayan D, Graves E, Bogdanov A, Jr, Josephson L, Weissleder R. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A. 2004;101:12294–12299. [PubMed]

21. Shepherd J, Hilderbrand SA, Waterman P, Heinecke JW, Weissleder R, Libby P. A fluorescent probe for the detection of myeloperoxidase activity in atherosclerosis-associated macrophages. Chem Biol. 2007;14:1221–1231. [PubMed]

22. Waldeck J, Hager F, Holtke C, Lanckohr C, von Wallbrunn A, Torsello G, Heindel W, Theilmeier G, Schafers M, Bremer C. Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alphavbeta3 integrin-targeted fluorochrome. J Nucl Med. 2008;49:1845–1851. [PubMed]

23. Park K, Hong HY, Moon HJ, Lee BH, Kim IS, Kwon IC, Rhee K. A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. J Control Release. 2008;128:217–223. [PubMed]

24. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol. 2007;3:668–677. [PubMed]

25. Cheng Z, Levi J, Xiong Z, Gheysens O, Keren S, Chen X, Gambhir SS. Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem. 2006;17:662–669. [PubMed]

26. Kovar JL, Volcheck W, Sevick-Muraca E, Simpson MA, Olive DM. Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. Anal Biochem. 2009;384:254–262. [PubMed]

27. Faust A, Waschkau B, Waldeck J, Holtke C, Breyholz HJ, Wagner S, Kopka K, Heindel W, Schafers M, Bremer C. Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix metalloproteinases. Bioconjug Chem. 2008;19:1001–1008. [PubMed]

28. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003;63:8122–8125. [PubMed]

29. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med. 2005;53:999–1005. [PubMed]

30. Mani V, Briley-Saebo KC, Itskovich VV, Samber DD, Fayad ZA. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med. 2006;55:126–135. [PubMed]

31. Farrar CT, Dai G, Novikov M, Rosenzweig A, Weissleder R, Rosen BR, Sosnovik DE. Impact of field strength and iron oxide nanoparticle concentration on the linearity and diagnostic accuracy of off-resonance imaging. NMR Biomed. 2008;21:453–463. [PubMed]

32. Korosoglou G, Weiss RG, Kedziorek DA, Walczak P, Gilson WD, Schar M, Sosnovik DE, Kraitchman DL, Boston RC, Bulte JW, Weissleder R, Stuber M. Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using “positive contrast” magnetic resonance imaging. J Am Coll Cardiol. 2008;52:483–491. [PubMed]

33. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–2499. [PubMed]

34. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453–2458. [PubMed]

35. Trivedi RA, U-King-Im J, Graves MJ, Cross JJ, Horsley J, Goddard MJ, Skepper JN, Quartey G, Warburton E, Joubert I, Wang L, Kirkpatrick PJ, Brown J, Gillard JH. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35:1631–1635. [PubMed]

36. Trivedi RA, Mallawarachi C, U-King-Im J, Graves MJ, Horsley J, Goddard MJ, Brown A, Wang L, Kirkpatrick PJ, Brown J, Gillard JH. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006;26:1601–1606. [PubMed]

37. Tang T, Howarth SP, Miller SR, Trivedi R, Graves MJ, U-King-Im J, Li ZY, Brown AP, Kirkpatrick PJ, Gaunt ME, Gillard JH. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke. 2006;37:2266–2270. [PubMed]

38. Tang TY, Howarth SP, Miller SR, Graves MJ, UK-I JM, Li ZY, Walsh SR, Patterson AJ, Kirkpatrick PJ, Warburton EA, Varty K, Gaunt ME, Gillard JH. Correlation of carotid atheromatous plaque inflammation using USPIO-enhanced MR imaging with degree of luminal stenosis. Stroke. 2008;39:2144–2147. [PubMed]

39. Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A. 2004;101:12634–12639. [PubMed]

40. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol Imaging. 2006;5:85–92. [PubMed]

41. Pande AN, Kohler RH, Aikawa E, Weissleder R, Jaffer FA. Detection of macrophage activity in atherosclerosis in vivo using multichannel, high-resolution laser scanning fluorescence microscopy. J Biomed Opt. 2006;11:021009. [PubMed]

42. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117:379–387. [PubMed]

43. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, Thielscher A, Kneilling M, Lichy MP, Eichner M, Klingel K, Reischl G, Widmaier S, Rocken M, Nutt RE, Machulla HJ, Uludag K, Cherry SR, Claussen CD, Pichler BJ. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459–465. [PubMed]

44. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005;96:327–336. [PubMed]

45. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114:1504–1511. [PubMed]

46. Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Reynolds F, Grazette L, Rosenzweig A, Weissleder R, Josephson L. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med. 2005;54:718–724. [PubMed]

47. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v) beta3-integrin-targeted nanoparticles. Circulation. 2003;108:2270–2274. [PubMed]

48. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008;60:1241–1251. [PubMed]

49. Cormode DP, Skajaa T, Fayad ZA, Mulder WJ. Nanotechnology in Medical Imaging. Probe Design and Applications. Arterioscler Thromb Vasc Biol. In press.

50. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99:1726–1732. [PubMed]

51. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med. 2007;4:491–502. [PubMed]

52. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2103–2109. [PubMed]

53. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic Synergism of Integrin-Targeted Fumagillin Nanoparticles and Atorvastatin in Atherosclerosis. J Am Coll Cardiol Img. 2008;1:624–634.

54. Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, Wickline SA, Lanza GM. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 2008;22:4179–4189. [PubMed]

55. Tawakol A, Castano AP, Gad F, Zahra T, Bashian G, Migrino RQ, Ahmadi A, Stern J, Anatelli F, Chirico S, Shirazi A, Syed S, Fischman AJ, Muller JE, Hamblin MR. Intravascular detection of inflamed atherosclerotic plaques using a fluorescent photosensitizer targeted to the scavenger receptor. Photochem Photobiol Sci. 2008;7:33–39. [PubMed]

56. McCarthy JR, Jaffer FA, Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small. 2006;2:983–987. [PubMed]

57. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007;13:372–377. [PubMed]

58. Callahan RJ, Bogdanov A, Jr, Fischman AJ, Brady TJ, Weissleder R. Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging. AJR Am J Roentgenol. 1998;171:137–143. [PubMed]

59. Shah K, Weissleder R. Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx. 2005;2:215–225. [PubMed]

Formats:

PubMed articles by these authors

PubMed related articles

Recent Activity

Links